For more infomaton on Trials please contact Susan Nelson ssnelson@jdrf.org or go to **https://clinicaltrials.gov**

Study Type	Age	Study Name and purpose	Local Location	Contact	Basic Inclusion Criteria	Commitment	Status
Behavior	18-30	Evaluation of an Intervention for Young Adults With Diabetes: Resilient, Empowered, Active Living-Telehealth (REAL-T)	University of Southern California	Beth Pyatak/Elissa Lee, University of Southern California elissale@usc.edu	Type 1 diabetes for at least 1 year Willing to participate in a 6 month intervention	Participants receive approximately 12 hours of intervention, delivered via telehealth over 6 months by a licensed occupational therapist with training in diabetes education, motivational interviewing, and the REAL Diabetes intervention protocol.	11/21/20 Actively Recruiting
Behavior	4-18	Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents With Type 1 Diabetes	Children's Hospital Los Angeles,CA	Joselyn Ruiz 323-361-8884 ext 18884 joselynruiz@chla.usc.edu	TBD	Not yet established	not yet recruiting
Prevention	2.5-45	TrialNet: Pathway to Prevention AntibodyScreening. Determines risk for developing T1D in unaffected family members, providing opportunities to join in further trials if at-risk Have a relative with T1D (siblings, cousins, etc. may be at a higher risk of developing T1D)	Various Locations or mail in	clinicalresearch@diabetes.ucsf.edu 844- T1D-UCSF (844-813-8273)	Have a relative with T1D (siblings, cousins, etc. may be at a higher risk of developing T1D)	Blood test to mail in or take to LabCorp	11/20/20 Actively Recruiting
Prevention	18-45	An Immunotherapy Vaccine (PIpepTolDC) for the Treatment of Patients With Type 1 Diabetes	City of Hope Duarte, CA	Ryotaro Nakamura 866-444-7538 DL-TolDC@coh.org	Check Study for Criteria Data		Recruiting
Prevention	under 1 year	Understanding Beta-cell Destruction Through the Study of EXtremely Early-onset Type 1 Diabetes (A Musketeers' Memorandum Study)	City of Hope Duarte, CA	Bart Roep broep@coh.org	Check Study for Criteria Data	The aim of this work is to study very unusual people who develop T1D extremely young, as babies under 1 year of age. The investigators think that, for the condition to have developed that early, they must have an unusual or extreme form of autoimmunity.	not yet recruiting
Prevention	3+	This study is testing a medication, called hydroxychloroquine (HCQ) to assess safety and effectiveness to prevent individuals at risk of type 1 diabetes (T1D) from progressing to type 1 diabetes.	Children's Hospital Los Angeles,CA	Roshanak Monzavi, MD	Positive for 2 or more autoantibodies; not diagnosed with T1D.	Blood test	Recruiting
Device	17-70	Randomized Crossover Euglycemic Clamp Study in Adult Patients With **Type 1 Diabetes** to Assess Pharmacokinetics and Pharmacodynamics of Subcutaneously Infused Insulin Using an Investigational Extended Wear Continuous Subcutaneous Insulin Infusion Cannula Compared to a Commercial Infusion Set	AMCR Institute Escondido, CA	877-567-2627 i Principal Investigator: Timothy Bailey info@amcrinstitute.com	Check Study for Criteria Data		Recruiting
Device	18+	A Randomized Crossover Comparison of Artificial Pancreas vs. Sensor Augmented Pump/Predictive Low Glucose Suspend With Different Stress Assessments in the Outpatient Setting for Patients With Type 1 Diabetes	Sansum Diabetes Research Institute, Santa Barbara	Molly Piper 805 682 7640 ext 214 mpiper@sansum.org	Type 1 diabetes for at least 1 year	Participants will use the Automated Insulin Delivery (AID) iAPS system for 2 weeks in the outpatient setting, and come to the clinical center twice for supervised stress assessments	Recruiting
Device	18+	This clinical trial is a safety and feasibility study to assess the performance of an artificial pancreas (AP) system using the Zone Model Predictive control (Zone-MPC) and Health Monitoring System (HMS) algorithms embedded into the iAPS platform for pregnant patients with type 1 diabetes (T1D).	Sansum Diabetes Research Institute, Santa Barbara	Jordan E Pinsker, MD jpinsker@sansum.org	Pregnant women 18 years of age or older with T1D	Participants will use the Automated Insulin Delivery (AID) iAPS system for 48-60 hours in a medically supervised session.	Recruiting
Device	18+	The overall goal of this study is to enroll pregnant women with type 1 diabetes and follow their glycemic outcomes prospectively throughout pregnancy and into the post-partum period.	Sansum Diabetes Research Institute, Santa Barbara	Camille Andre candre@sansum.org	Pregnant women 18 years of age or older with T1D using an insulin pump	The overall goal of this study is to enroll pregnant women with type 1 diabetes and follow their glycemic outcomes prospectively throughout pregnancy and into the post-partum period	Recruiting
Device	18+	Managing Type 1 and High Risk Type 2 Diabetes in the Hospital Setting: Glucose as a Vital Sign	Scripps Whittier Diabetes Institute, La Jolla, CA	Athena Philis-Tsimikas, MD	Type 1 diabetes, high risk type 2 diabetes	All patients with type 1 or type 2 diabetes who meet study criteria will be invited to participate in the study. All patients included in the study will be followed by an advanced practice diabetes nurse for glucose management during their hospitalization. All patients included in the study will receive a CGM.	Recruiting

Drug	18-68	Improving Islet Transplantation Outcomes With Gastrin	City of Hope Duarte, CA University of California, Los Angeles	Fouad Kandeel, MD, PhD	Proportion of subjects who are insulin independent, free from severe hypoglycemia and have HbA1c less than or equal to 6.5% ("complete response") [Time Frame: 1 year post		not yet recruiting
Drug	18-65	A pilot study for individuals with Type 1 Diabetes who are willing to add an SGLT-2i (Sodium-Glucose Cotransporter-2 Inhibitor) in combination with placebo or a GRA (Glucagon Receptor Antagonist) to their current diabetes treatment regimen.	UC San Diego Altman Clinical & Translational Research Institute	tmay@health.ucsd.edu	type 1 diabetes more than 5 years Use of a CGM	There will be 15 study visits over approximately 14 weeks in this cross-over study design. Treatment "A" consists of an SGLT-2i + GRA for 4 weeks and treatment "B" consists of an SGLT-2i + placebo for 4 weeks. All participants will complete both treatment "A" and treatment "B" with a 6-week washout period in between the treatments. Testing includes	not yet recruiting
Drug	18-65	This study will determine whether REMD-477 can decrease daily insulin requirements and improve glycemic control after 12 weeks of treatment in subjects diagnosed with Type 1 diabetes	AMCR Institute, Escondido, CAAltman Clinical and Translational Research Institute, San Diego	Timonthy S Bailey, MD 760-466-1523 Todd May tmay@ucsd.edu	Check Study for Criteria Data	Administered as a repeated subcutaneous (SC) doses in subjects with Type 1 Diabetes Over a 12 week period	Recruiting
Drug	1-17	Testing Lyumjev, a new faster- acting insulin developed by Eli Lilly. This study will be comparing Humalog with this faster-acting insulin. This insulin has already been approved for adults.	Coastal Metabolic Research Centre Ventura, California, United States, 93003	Dr. Ronald Chochinov 8056673909	T1D for at least 6 months and currently on MDI.	8-9 months, with 7 in-person visits.	11/21/20 Recruiting
Drug	18+	This study will determine if drug LY3209590 is safe and effective in participants with type 1 diabetes.	Coastal Metabolic Research Centre Ventura, California, United States, 93003	Dr. Ronald Chochinov 8056673909	T1D for at least 1 year and currently MDI	study will last up to 33 weeks and may include up to 21 visits	Recruiting
Drug/Newly Diagnosed	12-40	A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recently Diagnosed Type 1 Diabetes Mellitus (T1D)	Coastal Metabolic Research Centre Ventura, California, United States, 93003	Dr. Ronald Chochinov 8056673909	initiate study drug must take place within 150 days of diagnosis	Subjects will receive two courses of either teplizumab or placebo treatment 6 months apart.	Recruiting
Drug/Newly Diagnosed	8-17	Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab	Rady Children's Hospital-San Diego (Site 004)	Michael Gottschalk, MD 858-966-8400 EndoResearch@rchsd.org.edu	Is able to be randomized and initiate study drug within 6 weeks (42 days) of the formal T1D diagnosis.	Subjects will receive two courses of either teplizumab or placebo treatment 6 months apart.	Recruiting